Legend Biotech shared its earnings call, showing a 36% jump in CARVYKTI sales to $710 million.

Nov 10, 2026, 9:21 AM ETResultsRead the original at Benzinga

Good for LEGN

Legend Biotech reported CARVYKTI sales rose 36% to $710 million and a study found 69% survival after 5 years. Its 2026 profit goal remains a target and LB2501 is still being studied, but sales growth supports a favorable read.

LEGN · Legend Biotech

AI read · Good for LEGN

The AI's read

This gives Legend more sales from its lead treatment and cash to keep developing its medicines. Long-term study results also add support for CARVYKTI's potential in earlier treatment. But the 2026 profit goal is still a target, and LB2501 is still being studied.

Get alerts for LEGN

Follow Legend Biotech (LEGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LEGN

Free on the App Store and Google Play, or on the web.